Cargando…
SUN-254 A Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human Growth Hormone (rhGH), in Short Children Born Small for Gestational Age (SGA)
Background: Children born SGA are predisposed to metabolic abnormalities. While the therapeutic benefit of rhGH therapy in improving height is widely recognised, it can affect carbohydrate metabolism, potentially inducing diabetes. This ongoing, prospective study aims to evaluate the long-term safet...
Autores principales: | Schwarz, Hans-Peter, Giemza, Tomasz, Jathanakodi, Shrihari, Zouater, Hichem, Zabransky, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552986/ http://dx.doi.org/10.1210/js.2019-SUN-254 |
Ejemplares similares
-
Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
por: Lundberg, Elena, et al.
Publicado: (2020) -
Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland
por: Glińska, Marta, et al.
Publicado: (2022) -
Long-term follow up of carbohydrate metabolism and adverse events after termination of Omnitrope® treatment in children born small for gestational age
por: Walczak, Mieczyslaw, et al.
Publicado: (2021) -
SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019) -
Noonan syndrome: rhGH treatment and
PTPN11
mutation
por: Wu, Xian, et al.
Publicado: (2023)